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Hereditary tyrosinemia is an inborn error of tyrosine metabolism due to an 
inherited deficiency of fumarylacetoacetate hydrolase activity transmitted in an 
autosomal recessive fashion (1).  This disease is characterized by multiple renal 
tubular defects accompanied with aminoaciduria and proteinuria,  nodular cir- 
rhosis, vitamin D-resistant  (hypophosphatemic) rickets, and occasionally symp- 
toms resembling those of acute intermittent porphyria (AIP) 1 (1, 2).  Hepatoma 
is a quite frequent complication ~40% of patients suffering ultimate liver failure 
(3). Patients with this hereditary disease excrete large amounts of 4,6-dioxohep- 
tanoic acid (succinylacetone [SA]) (4), and the presence of SA is thought to be a 
specific  biochemical  marker  of  this  disease.  SA  in  biological  fluids  can  be 
determined  by  gas  chromatography  (4,  5)  or  indirectly  by  inhibition  of  6- 
aminolevulinic acid (ALA) dehydratase, because the compound is an extremely 
potent inhibitor of this enzyme in human as well as in animal tissues (6, 7). 
During the course of our studies of tyrosinemia, we observed that urines of 
patients with hereditary tyrosinemia contain a  material(s) that absorbs  light at 
315  nm.  The  315  nm  material  occurs  in  urines  from  patients  with  tyro- 
sinemia, but not in normal controls, nor in patients with other forms of amino- 
aciduria or proteinuria. This phenomenon led us to examine the nature of the 
315 nm material in detail. We report in this paper that SA reacts nonenzymati- 
cally with various amino acids and proteins such as albumin at physiological pH 
and temperature, and forms stable adducts that have an absorption maximum at 
315 nm. High-performance liquid chromatography (HPLC) and thin layer chro- 
matography (TLC) analyses of urines demonstrated that a  large amount of SA 
adducts with amino acids and protein  (presumably albumin) are excreted into 
the urine of patients with hereditary tyrosinemia, but not in control subjects or 
in patients with other disorders. 
Materials and Methods 
Materials.  SA was purchased from Calbiochem-Behring Corp. (San Diego, CA). Amino 
acids, reduced glutathione (GSH), and human serum albumin (fraction V) were obtained 
from Sigma Chemical Co. (St. Louis, MO). Proteinase K was from Boehringer Mannheim 
Biochemicals (Mannheim, Federal Republic of Germany). All other chemicals were of 
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analytical  grade.  [14C(U)]iysine ([14C]Lys)  (324.7  mCi/m  mol)  was obtained  from  New 
England Nuclear (Boston, MA). 
Urine samples of three patients with hereditary tyrosinemia, two patients with Fanconi 
syndrome and two patients with nephrotic syndrome were obtained from the New York 
Hospital-Cornell  University  Medical  Center  (New  York),  and  the  Children's  Hospital 
Medical Center-Harvard  Medical School (Boston, MA), and urine samples of six normal 
subjects  and  two  patients  with  AIP  were  obtained  from  The  Rockefeller  University 
Hospital. All urine samples were stored at -20°C until use. 
Spectrophotometric Analyses of SA-Amino Acid Adducts.  Urine samples were diluted 50- 
fold with distilled water before determination. SA (1 mM) was dissolved in 50 mM sodium 
phosphate  buffer  at  various  pH.  After  confirming  the  pH  of the  final  solution,  the 
absorbance spectrum of SA was examined.  To prepare  the SA-amino acid adduct,  SA 
and amino acids were dissolved in 50 mM sodium phosphate buffer, pH 7.4, and incubated 
at 37°C. Absorbance spectra were obtained at intervals using the nonincubated solution 
as the blank.  Spectrophotometric measurements  of urine samples were performed on a 
CARY 118 spectrophotometer (Varian Associates, Inc., Palo Alto, CA). 
To determine  the reactivity of amino acids with SA,  the increment of absorbance at 
315 nm with time was recorded. Effects of pH on the stabilities of SA-amino acid adducts 
that had or had not been reduced with sodium borohydride were examined by recording 
the absorbance spectrum at various pH between  1.0 and 9.0. 
Preparation  of SA-Albumin  Adducts.  Human  serum  albumin  was  incubated  with  or 
without 25 mM SA in 50 mM sodium phosphate buffer, pH 7.4, for 10 min, or for 24 h 
at  37°C.  Final concentrations of SA and albumin  were 25  mM and  50 mg/ml (or 750 
#M),  respectively. The mixture was then dialyzed overnight using a  Spectrapor dialysis 
membrane (cutoff, 6,000-8,000 mol wt) at 4 °C against 50 mM phosphate buffer, pH 7.4. 
The dialyzed albumin and SA-albumin were filtered through a Millipore filter (0.45 ~m) 
(Bedford, MA). Absorbance of the filtrate was determined spectrophotometrically. Protein 
concentrations were determined by the method of Lowry et al. (8).  In some experiments, 
SA-albumin  was reduced  with  NaBH4 before digestion  with  proteinase  K  as described 
below. 
Enzymatic Digestion.  Albumin and SA-albumin (5 mg protein) were digested  with an 
equal volume of the digestion buffer (0.1  M Tris-HCl, pH 8.8 containing  1 mM EDTA 
and 1 mM dithiothreitol) and 1 mg/ml proteinase K (9). The mixture was then incubated 
at 37°C.  Proteolysis was determined to be complete in 2 h, as judged by the generation 
of ninhydrin-positive  material  (10).  After digestion,  extraction  of SA-adducts that  had 
been released from proteins was carried out as described below. 
For enzymatic digestion of proteins  in urine,  20 ~1 of a  mixture containing 500 mM 
EDTA, pH 8.0, and proteinase K (final concentration, 0.5 mg/ml) were added to a  10-mi 
urine  sample  (pH  7.4)  that  had  been  diluted  with  an  equal  volume of distilled  water. 
Digestion was carried out at 37°C for 2 h. 
Extraction of SA and SA-Amino Acid Adducts from Urine.  To determine the rate of the 
extraction of SA and SA adducts in urine, SA or SA-Lys was added to 10 ml normal urine 
that  had  been  adjusted  to pH  7.4  (final  concentration,  5  mM as SA),  with  or without 
proteinase  K, and extracted  at pH  7.4,  once with  two volumes of ethylether and once 
with two volumes of chloroform/methanol (2:1 vol/vol), and dried under nitrogen stream. 
The extracts  were dissolved in  50%  methanol  in water,  and  filtered  through a  Millex- 
HV4 filter (Millipore) for HPLC analysis. 
HPLC Analyses.  HPLC analyses were carried out on a ttBondapack C~s column (300 
×  4 mm; Waters Associates, Milford, MA) using a Series 3 liquid chromatograph (Perkin- 
Elmer Corp., Norwalk, CT) equipped with a LC-75 spectrophotometric detector (Perkin- 
Elmer  Corp.).  The  solvent  systems  used  were  as  follows:  the  starting  eluent,  20  mM 
potassium phosphate  buffer,  pH  7.0,  the  limiting eluent,  methanol/water  (1:1  vol/vol), 
linear gradient elution, from 0 to 100% of the limiting eluent in the starting eluent over 
a course of 30 min. A  flow rate of 1.0 ml/min was used. Absorbance was determined at 
315 nm for SA-amino acid adducts, 280 nm for SA and 210 nm for Lys, respectively. 
TLC Analyses.  We added  1 ml of SA (100 mg) to 0.5 ml of 10 mM Lys containing 10 1062  HEREDITARY TYROSINEMIA 
~tCi of [14C]Lys, and incubated for 24 h at 37°C. The mixture was reduced with NaBH4 
and was spotted on a  silica  gel 60 plate (E.  M.  Merck,  Darmstedt,  Federal  Republic of 
Germany).  Compounds  were  visualized  by  iodide  vapor,  and  then  autoradiographed. 
Exposure  was  performed  with  Kodak  X-OMATAR5  X-ray film  (Eastman  Kodak Co., 
Rochester,  NY)  for  7  d.  Urine samples,  and  SA-albumin that  had  been  digested  with 
proteinase K and then reduced with NaBH4, were extracted with ethylether, followed by 
chloroform/methanol (2:1  vol/vol). Dried materials were dissolved in 50%  methanol  in 
water, and spotted on a silica gel 60 plate. The solvent used for separation was a mixture 
of isopropanol in 5% ammonium hydroxide (4:1 vol/vol). 
Results 
Absorbance Spectra  of Urine Samples.  All  urine  samples  from  three  patients 
with hereditary tyrosinemia showed an absorption maximum at 315 nm.  Repre- 
sentative  absorption  spectra  from a  patient  with  tyrosinemia  are  shown  in  Fig. 
1 A.  The  peak  at  315  nm  in  the  absorbance  spectrum  was increased  when  the 
pH was elevated to 7.4. When SA-Lys was added to the urine sample, it increased 
the absorbance  at  315  nm.  In contrast,  urine  samples  from six normal subjects 
and  from six  patients  with  other  diseases,  including  AIP,  nephrotic  syndrome, 
and  Fanconi  syndrome,  did  not show an absorption  peak at  315  nm (Fig.  1B). 
Addition of SA (100  ~tM)  to normal  urine did not change the spectrum.  A  315 
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FIGURE 1.  Ultraviolet  (UV) absorbance spectra of urine Samples from a normal subject and 
a patient with hereditary tyrosinemia. A, (O) Urine from a patient with hereditary tyrosinemia 
diluted 50-fold  with distilled  water;  (- - -) after incubation  of the diluted urine sample at 
37°C, for 30 min at pH 7.4; (0) after addition of SA-Lys (20 tzM), to the diluted urine. B, (O) 
Urine from a normal subject diluted 50-fold with distilled water; (- - -) after addition of SA 
(100 #M, final concentration) to the diluted normal urine at pH 7.4; (0) after addition of SA- 
Lys (50 #M) to the diluted normal urine. MANABE  ET  AL.  1063 
nm  absorbance  material,  however,  could  be  readily  demonstrated  in  normal 
urine when it was incubated with SA-Lys (50 ~M) (Fig.  1B).  In addition to the 
315 nm peak,  tyrosinemia urines contained material(s) with an absorption peak 
at  260  nm,  which  most likely  reflects  the high  phenylalanine  content of these 
urine samples. 
Absorbance Spectra  of SA and SA-Amino Acid Adducts.  SA has an absorbance 
peak at 280 nm at pH 7.4, while Lys has no absorption at this wavelength (Fig. 
2).  When  UV absorbance spectra of the mixture were recorded  using a nonin- 
cubated mixture of SA and Lys as reference,  a new absorption maximum similar 
to Fig.  1 appeared  at 315  nm,  indicating  that SA nonenzymatically  formed an 
adduct with Lys. 
Relationships between absorbance and concentrations of SA and SA-Lys were 
examined (Fig. 3). SA and SA-Lys were determined at pH 7.4 at their absorption 
maxima,  i.e.,  at  280  and  315  nm,  respectively  (Fig.  3).  The  concentrations  of 
SA-Lys adducts were expressed as SA equivalents. There was a linear relationship 
between  the  concentration  and  the  absorbance  of  SA  and  SA-Lys  (Fig.  3). 
Minimal detection limits, i.e., an absorbance of 0.02, were  12.8 ~M for SA and 
1.3 ~M for SA-Lys, respectively. 
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FIGURE  9.  UV absorbance spectra of Lys, SA, and SA-Lys. Concentrations of Lys, SA, and 
SA-Lys were 0.3 mM, 0.3 mM and 0.1  mM, respectively. 
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FIGURE  3.  Absorbance  of SA  and  SA-Lys  as  a  function  of their  concentrations.  SA-Lys 
adducts were prepared by incubating SA with Lys (100-fold excess) at pH  7.4 for  24 h.  SA 
concentration was determined at 280 nm, while SA-Lys concentration was determined at 31.5 
nm. SA-Lys concentration  was expressed as the corresponding SA concentration. 1064  HEREDITARY  TYROSINEMIA 
Absorbance  Spectra  of SA-Albumin  Adducts.  In  addition  to  amino  acids,  SA 
formed an  adduct  with  purified  human  serum  albumin  that  also  displayed  an 
absorbance maximum at  315  nm (data not shown).  The absorbance at 315  nm 
increased  linearly with  time and  reached  a  plateau  at  24  h  after incubation  of 
albumin with SA at 37°C at pH 7.4. 
Effects ofpH on Stability of SA.  To determine pH optima for the formation of 
SA  adducts  with  amino  acids  and  albumin,  absorbance  of  the  mixture  was 
continuously recorded at 315  nm at various pH. All adducts were stable at pH 
between  7  and  8  for at  least  1 mo at  37°C  (data not  shown).  However, within 
30  min,  SA  was completely released  from the  SA-amino acid adduct  at  a  pH 
lower  than  3.  The  SA-albumin  adduct  was  more  stable  than  SA-amino  acid 
adducts at a low pH, with about 10% of the adduct remaining after 2-h incubation 
at pH 3. 
SA  adducts  that  had  been  reduced  with  NaBH4  were  more  stable  than  the 
adduct  without  reduction.  Incubation  of the  SA-amino  acid adducts  that  had 
been  reduced  with  NaHB4 at pH  1.0  for  2  h  resulted  in a  loss of 50%  of the 
adducts.  The reduced SA-albumin was even more stable than  the reduced SA- 
amino acids,  in  that >60%  of the  adducts  were present after incubation  at pH 
1.0 for 2 h. 
Rate of Adduct Formation with SA.  20  amino acids  were  examined  for their 
reaction with SA.  All amino acids examined reacted with SA nonenzymatically, 
forming adducts as determined by the appearance of a new absorbance maximum 
at  315  nm.  In addition  to amino acids,  SA formed a  similar adduct  with  GSH. 
The rate of formation of the SA adduct with amino acids (40 mM) and GSH (40 
m M) was determined at 20 °C using an SA concentration of 1 raM. Representative 
results  are  shown  in  Fig.  4  for  the  SA  adduct  formation  with  Lys,  glycine, 
methionine, phenylalanine, serine, alanine, glutamine, and GSH. The SA adduct 
formation  was  most rapid  with  Lys,  followed in  order  by glycine,  methionine, 
phenylalanine,  GSH,  serine,  and  alanine,  and  was slowest  with  glutamine.  SA- 
adduct  formation increased  with time, and  reached a  maximum after 2  h  with 
Lys (Fig. 4), but took  12 h  with slow-reacting amino acids such as alanine. 
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FIGURE 4.  Rate of adduct  formation  of SA with amino acids as a function  of incubation 
period. Absorbance at 315 nm was continuously recorded with time after 1 mM SA was added 
to each amino acid (40 mM) in 50 mM sodium phosphate buffer, pH 7.4, at 20°C. MANABE  ET  AL.  1065 
Extraction  of SA  and  SA-Amino Acid Adducts from  Urine.  To determine  the 
rate of extraction  of SA and SA-Lys from urine,  they were extracted from  10 
ml normal urine after supplementation with each compound (5 mM) using ethyl 
ether,  followed by a  mixture  of chloroform/methanol  (2:1  vol/vol).  67.5%  of 
free SA was recovered at pH  1.0 and 29.4%  at pH  7.4.  34.6% of SA-Lys was 
recovered at pH 7.4, however, little SA-Lys was recovered at pH 1.0, as expected. 
64.5%  of SA-Lys was recovered  as  free  SA at  pH  1.0.  These  results  can  be 
explained by the fact that SA-Lys is readily dissociated into free SA and Lys at 
pH  1.  The  results  also suggest that  urine  samples extracted at pH  1.0  give a 
quantitative estimate of total SA, while urines extracted at pH 7.4 give a measure 
of the sum of free SA and SA-amino acid adducts. 
HPLC Analysis of Free SA and SA-Amino Acid Adducts.  An HPLC method was 
developed for the analysis of free SA and SA-amino acid adducts. As shown in 
Fig.  5A,  three  major peaks (A,  B, and  C) and two minor peaks were detected 
from a mixture of SA and Lys after incubation at pH 7.4 for 2 h, at 37°C, using 
absorbance at 315 nm.  These peaks chromatographed  entirely differently from 
free SA (Fig.  5A at 280 nm) and Lys (Fig. 5A at 210 nm), which were detected 
at  each  absorption  maximum,  i.e.,  280  and  210  nm,  respectively.  The  three 
major peaks (A, B, and C) had an identical absorption profile, with a peak at 315 
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FIGURE  5.  HPLC  chromatographic  profiles  of  SA,  Lys,  and  SA-Lys.  SA  (50  mM)  was 
incubated with 50 mM L-[14C]Lys (sp act 324.7 mCi/mmole) at 37°C for 24 h. The incubated 
mixture  was injected  into  HPLC  as described  in  Materials and  Methods.  (A)  315  nm;  SA- 
['4C]Lys detected at 315 nm. 280 nm; SA detected at 280 nm. 910 nm: Lys detected at 210 
nm. An increase in absorbance after the Lys peak is due to the absorption of methanol, which 
was used for gradient elution, at 210 nm. (B) Radioactivities of the above fractions (cf. Table 
1). 1066  HEREDITARY  TYROSINEMIA 
nm  (not  shown),  suggesting  that  all  three  peaks  represent  SA-Lys  adducts. 
Absorbance properties of the two minor peaks could not be examined, due to 
extremely low concentrations of these materials. 
A chromatographic profile of a  mixture of SA and [14C]Lys is shown in Fig. 
5B. The radioactive chromatographic profile is identical to the profile shown in 
the upper set, which had been examined at 210 and 315 nm. The molar ratio of 
SA/Lys in the SA Lys adducts was found to be -1.0 (Table I). In addition, there 
was no significant difference in the elution profile between SA-Lys and SA-Lys 
that had been reduced with NaBH4. 
At 315 nm, SA-Lys adducts had significantly greater absorption than free SA, 
on a  molar basis.  There was also a  linear relationship between the absorbance 
and the concentration of free SA or SA-Lys adducts. These properties allowed 
selective quantitation of free SA and SA-Lys adducts by HPLC. 
HPLC Analysis of Urine Samples.  Three patients with hereditary tyrosinemia, 
six other patients (two with Fanconi syndrome, two with nephrotic syndrome, 
and two with AIP), and six normal subjects were studied. SA-amino acids were 
detected in all  12  urine samples examined from the 3 patients with hereditary 
tyrosinemia. A  typical chromatogram is  shown in  Fig.  6.  An  untreated urine 
specimen from a  patient with tyrosinemia showed four major peaks (Fig. 6A), 
which  corresponded  to  SA-glycine,  SA-methionine,  SA-tyrosine,  and  SA- 
phenylalanine (Fig. 6 C).  After digestion of the urinary sample with proteinase 
K, three more new peaks appeared on the chromatogram (Fig. 6B),  three of 
which corresponded to SA-Lys (Fig. 6 C). The fact that these peaks are derived 
from SA-Lys was also confirmed by collecting these peaks, and by reanalysis by 
TLC.  In  contrast to  tyrosinemia, SA  adducts were  not detected in  urines of 
normal  subjects  or  patients  with  Fanconi  syndrome, nephrotic  syndrome, or 
AIP. 
Chromatographic  Identification of SA-Lys Derived from SA-Albumin in Tyrosinemia 
Urine.  Albumin that had been incubated with excess SA at pH 7.4 for 24 h did 
not exhibit any HPLC peaks corresponding to SA-amino acid adducts, including 
that of SA-Lys (data not shown).  In contrast, three peaks that are identical to 
SA-Lys (Fig.  6C)  were detected in an  SA-albumin preparation that had been 
digested  with  proteinase  K  (Fig.  7A).  The  fact  that  these  three  peaks  were 
derived from  SA-Lys was  confirmed by rechromatography of these peaks  by 
TLC (data not shown). 
TABLE  I 
Molar Ratios of Lys to SA in SA-Lys Adduct 
Molar 
SA-Lys peak  Lys  SA  Lys:SA  Lys:SA  ratio 
cpm  t~mole  cpm  /tamole 
A  13,115  47.3  277  1.1 
B  4,346  17.6  247  1.0 
C  9,607  32.3  298  1.2 
SA concentrations  and radioactivities  of [14C]Lys (sp act 250 cpm]~mole) were 
determined in the three major fractions from SA-Lys  adducts (A, B, and C in 
Fig. 5 B). After HPLC, SA was measured by converting  the adduct to free SA 
and Lys by lowering  pH to 1.0. MANABE  ET  AL.  1067 
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FIGURE 6.  HPLC chromatographic profile of a urine sample from a patient with hereditary 
tyrosinemia. A, untreated urine; B, urine treated with proteinase  K; C, mixture of SA-amino 
acid adducts.  SA-amino acid adducts were prepared by incubation of SA with excess amino 
acids at pH 7.4 for 24 h at 37°C. Details for HPLC analysis and for incubation are described 
in Materials and Methods. 
TLC  offered a  more extensive  resolution  of SA-Lys adducts  than  the  HPLC 
method  (Fig.  8).  When  the extract  of SA-albumin  that had  been  digested  with 
proteinase  K  was  rechromatographed  by  TLC,  at  least  seven  distinct  bands 
derived  from SA-Lys were detected.  Rf for SA was found to be 0.60,  and 0.58, 
0.50,  0.39,  0.35,  0.25,  0.16,  and  0.10  for SA-Lys (Fig.  8),  while  Lys remained 
at the origin in this system. The  same bands as seen  in the SA-Lys adducts were 1068  HEREDITARY  TYROSINEMIA 
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FIGURE 7.  Demonstration of SA-Lys in SA-albumin after digestion with proteinase K. Human 
serum albumin (50 mg/ml) was incubated with or without SA (25 mM) at 37 °C for 24 h. The 
mixture was  then  exhaustively dialyzed  against  50  mM  sodium phosphate buffer,  pH  7.4. 
After reduction with NaBH4, the mixture was incubated with proteinase K, at 37°C, for 2 h. 
A, SA-albumin after treatment with proteinase K; B, SA-albumin after treatment with protein- 
ase K, mixed with SA-Lys.  Nonincubated SA-albumin did not show any absorbance maxima 
under the condition of the assay (curve not shown). 
FIGURE 8.  TLC  separation of SA-Lys.  SA-[~4C]Lys  was chromatographed after reduction 
with  NaBH4.  Compounds  were  visualized by  iodide  vapor (tracing on  the  left),  and  then 
autoradiographed (right). 
seen in both SA-albumin and urine samples from patients with tryosinemia, both 
of which had been digested with proteinase  K  (data  not shown).  These results 
support the idea that  SA binds to a  Lys residue in albumin,  and the three new 
peaks that appeared in the HPLC chromatogram after digestion of urine samples 
with  proteinase  K  (Fig.  7B)  are  in  fact  SA-Lys derived  from  the  SA-bound 
protein. 
Effects of SA and SA-Lys on Activity  of ALA Dehydratase.  The effects of SA and 
SA-Lys on the activity ofALA dehydratase were examined using a homogenously 
purified enzyme from mouse liver. The enzyme reaction was carried out at pH 
7.4 to assure the stability of SA-Lys. Under these conditions, both SA and SA- 
Lys  inhibited  the  activity  of  ALA  dehydratase,  and  the  extent  of  enzyme 
inhibition  by free SA (65% at  10  -6  M) and SA-Lys (60% at  10  -6 M) was almost 
identical. MANABE  ET  AL.  1069 
Discussion 
The results of this study show that SA reacts with amino acids and/or proteins 
such as albumin to form stable adducts at physiological pH and temperature. Lys 
is the most reactive amino acid with SA, among the 20 amino acids examined. 
These adducts all absorbed light at 315 nm and exhibited a significantly greater 
absorbance  than  free  SA  or  amino acids at  this  wavelength.  Lys residues  in 
albumin also react with SA  to form a  stable adduct that can be  identified by 
HPLC or by TLC after digestion of the protein with proteinase K. This finding 
suggests that chromatographic detection of the SA-Lys residue in the protein 
can be accomplished only after proteolytic cleavage of the protein. 
Recently, Monnier and Cerami (11)  showed that glucose can react with the 
amino groups of various proteins nonenzymatically to form stable adducts. The 
significance of this  finding is  critical,  in  that  it  provides  a  new  approach  to 
examine the  nature of the crosslinking formed during aging of proteins and 
nucleic acids (12).  SA also presumably forms an adduct with an amino acid or a 
protein via a  Schiff base, since the adducts are stable at neutral pH, while they 
are quite unstable at low pH, e.g., pH  1.  In addition, the adducts were made 
more stable after reduction with NaBH4. Based on the absorbance of SA-Lys at 
315 nm (molar absorbance --  1.09 x  104) (Fig. 3), the amount of SA bound per 
mole  of albumin  was  calculated.  In  the  human  serum  albumin  solution  (50 
mg/ml =  750 gM) incubated with excess SA (25 mM) at 37°C for at least 24 h, 
the amount of SA bound was found to be 700 uM, indicating an approximately 
equimolar ratio of SA to albumin in the adduct. Since it is known that human 
serum albumin contains 58  Lys residues, the amount of Lys residues reacted 
with succinylacetone in the albumin was >2%.  Reactivity of Lys in albumin is 
not uniform, in that nonenzymatic glycosylation of Lys of human serum albumin 
is known to occur only at Lys 525 (13).  Whether Schiff base formation with Lys 
and SA also occurs at Lys 525 is not known, but SA probably only reacts with a 
highly reactive Lys in albumin. 
SA  in biological fluids occurring in patients with hereditary tyrosinemia has 
been determined either by gas chromatography (4,  5),  or by inhibition of the 
activity of ALA dehydratase activity by adding urine or plasma from the patients 
to the enzyme preparation (7).  However, the gas chromatographic method does 
not  discriminate free  SA  from  SA-amino acid adducts,  and  it  was  not  clear 
whether the enzyme-inhibition assay discriminates free SA from SA-Lys adducts. 
Our data show that both free SA and SA-Lys equally inhibited the activity of 
ALA dehydratase, indicating that the enzyme inhibition assay does not discrim- 
inate the two forms of SA. In this study, we have developed new methods that 
can separately quantitate free SA and SA-amino acid adducts by spectrophotom- 
etry, TLC, or HPLC. Using these methods, we showed for the first time that 
SA-adducts with amino acids and/or proteins exist in biological fluids in patients 
with tyrosinemia. In fact, our data show that the majority of SA exists as SA- 
amino acids or SA-protein adducts in the urine from patients with this disease. 
The spectrophotometric assay takes advantage of the fact that SA-amino acid 
adducts have a characteristic absorbance maximum at 315 nm, while free SA has 
a maximum at 280 nm, and other amino acids absorb between 260 and 280 nm. 
The molar absorbance of the SA-amino acid adduct at 315 nm was found to be 1070  HEREDITARY TYROSINEMIA 
10-fold greater than that of free SA. The minimal detection limit for free SA 
is ~ 13 ~M, and it is 1.3 ~M for SA-Lys by the spectrophotometric assay. 
Our results show that all three patients with hereditary tyrosinemia examined 
excreted significant amounts of SA-amino acid adducts into their urine, while 
patients with other aminoacidurias, such as  Fanconi syndrome and nephrotic 
syndrome, or patients with neurological abnormalities similar to those sometimes 
observed in tyrosinemia, such as AIP, did not show any detectable amounts of 
SA-amino  acid  adducts;  neither  did  normal  subjects.  Since  the  majority  of 
patients with tyrosinemia excrete large amounts of amino acids and/or proteins 
into their urine, it is likely that SA in their urine binds to amino acids or proteins 
nonenzymatically. Consistent with this view, we found that SA in the urine of 
patients with tyrosinemia exists, by and large, in the form of SA-protein adducts 
(average,  90%),  while <10%  exists as free SA.  These results suggest that the 
spectrophotometric assay of SA adducts in the urine from patients might be very 
useful in screening for tyrosinemia. 
Our HPLC method is able to separate free SA and each individual SA-amino 
acid in biological fluids in an unequivocal fashion. The resolution of free SA and 
individual SA-amino acid adducts is nearly complete, and is far more effective 
than the gas chromatographic separation of SA from other amino acids. Although 
the  minimum detection  limit  for  free  SA  and  SA-amino acid  at  280  nm  is 
comparable, i.e., 0.75 pmole, SA-amino acid can be detected at 315 nm with an 
-10-fold greater absorbance than at 280  nm. Separation of free SA and SA- 
amino acids can be  further facilitated by using solvent extraction at different 
pH. If extracted at neutral pH, e.g., pH 7.4, SA-amino acid was preferentially 
recovered, while if extracted at pH  1,  all  SA  (including SA  in the adduct) is 
recovered quantitatively as free SA, since all SA-amino acids and SA-proteins 
are readily dissociated into free SA and amino acids or proteins at the low pH. 
Thus, the extraction at pH  1 and the determination at 280 nm can be used for 
the total estimation and SA  in biological fluids, and the extraction at pH  7.4 
with determination at 315  nm can be used for the quantitation of the sum of 
free SA and SA-amino acid adducts occurring at the physiological pH. 
Using these procedures, the amount of free SA and SA-amino acid adducts 
in the urine of patients with tyrosinemia was estimated (Table II). When urine 
from patients with tyrosinemia was extracted at pH  7.4, without digestion with 
TABLE  II 
SA Concentrations in Urine from Patients with Hereditary Tyrosinemia 
Patient 
SA in urine 
With proteinase K  Without  proteinase K 
uM 
J.o.  10.0  71.60 
T.L.  0.80  42.45 
M.O.  0.45  9.85 
Urine samples with or without preincubation with proteinase K were analyzed 
by HPLC. Experimental  details  are described in Materials  and Methods. MANABE  ET  AL.  1071 
proteinase K, HPLC peaks corresponding SA-glycine, SA-methionine, SA-tyro- 
sine, and SA-phenylalanine were detected. These peaks were not observed in 
urines from normal subjects, nor in patients with Fanconi syndrome, nephrotic 
syndrome, nor AIP. It should be noted that not only tyrosine, but also methionine 
and phenylalanine are known to be elevated in the sera of patients with tyro- 
sinemia.  If, however, the extraction was made at pH  7.4  after digestion with 
proteinase K in order to release the SA-amino acid adduct in the protein, three 
new HPLC peaks (Fig. 6B) corresponding to SA-Lys (Fig. 6 C) were detected, in 
addition to the four SA-amino acid peaks that were present in the untreated 
urine from patients with tyrosinemia (Fig.  6A). This finding suggests that SA- 
Lys is derived from the Lys of proteins excreted into urine, presumably that of 
albumin. Moreover, significantly greater amounts of SA-amino acids (7- to 52- 
fold) were released from proteins  in  urine after digestion  with proteinase  K 
(Table  II),  suggesting that  the  majority of SA  in  the  urine  of patients  with 
tyrosinemia is present in the form of protein-SA adducts. 
TLC analysis also offered a  rapid  and simple separation  of individual  SA- 
amino acid adducts. As many as seven SA-Lys adducts could be identified after 
incubation of a mixture of SA and Lys at 37°C for 24 h (Fig. 8). Since [14C]Lys 
used in this study is radiolabeled either at the a- or the e-carbon position, eight 
different SA-Lys adducts could be hypothesized (Fig. 9). 
As shown previously (9,  11),  glucose and steroids form stable adducts with 
proteins, via a ketol moiety with the Lys residue in the protein. Since SA is a/3- 
diketone that is highly reactive and, as shown in our study, reacts with amino 
Succinylacetone 
(E ,,~) 
1 
,COOH 
,CH, 
CH= 
i 
O=C,  ~H= 
c<,  ~", 
CH= 
R-NH= (k-lysine) 
I 
I 
H ,,CH, 
R-tcc, 
"¢H, 
I 
~H~ 
gOOH 
CH, 
CH= 
CH= 
R-N< 
CH, 
( ~/e,  . ~/6  .  o./o,.  E;/6  ) 
FIGURE 9.  Possible structures of SA-Lys adducts. SA presumably binds with e-amino group 
of L-Lys.  Since [14C]Lys  used  in this study  is  radiolabeled either at the a- or  the e-carbon 
position, eight different SA-Lys species could be formed. 1072  HEREDITARY  TYROSINEMIA 
acids and albumin in vitro, we expect SA to react with amino acids and proteins 
in plasma or urine in patients with tyrosinemia. For example, the reaction rate 
of SA with Lys is greater than that of glucose or steroids (cortisol and predniso- 
lone) with  amino acids (9,  11,  12).  These  findings support  the idea that  the 
majority of SA in tissues, plasma, and urine in patients with tyrosinemia exists in 
the form of SA-protein adducts. 
It is known (1,  14) that treatment of patients with hereditary tyrosinemia with 
diets restricted in phenylalanine and tyrosine result in the reversal of the renal 
tubular dysfunction associated with the disorder. Renal tubular damage in these 
patients, as assessed by an increased excretion of/32-microglobulin, appears to be 
associated with an  increased excretion of SA and  succinylacetoacetate, which 
ensues from the administration of pbenylalanine and homogentisate (15). Since 
SA is highly reactive with proteins,  it might also be responsible for the renal 
tubular damage in patients with tyrosinemia. 
It has been reported (16) that the concentration of GSH in erytbrocytes and 
in  the liver in  a  patient with hereditary tyrosinemia was decreased. Our data 
indicate that SA reacts with GSH and forms a stable adduct (Fig. 4). Thus, excess 
SA produced in tyrosinemia may explain the apparent depletion of free GSH 
observed in patients with this disease. 
The human hereditary diseases such as ataxia teleangiectasia, Fanconi's ane- 
mia, and Bloom's syndrome are characterized by increased cancer incidence and 
spontaneous chromosomal breakage (17). All these disorders are associated with 
abnormalities in oxygen metabolism (18), and the involvement of prooxidants in 
the carcinogenesis associated with these disorders has been postulated (19). The 
incidence of hepatoma is extremely high in patients with tyrosinemia (as many 
as  37%  of the patients  who survive early liver failure will  develop hepatoma 
during childhood) (3).  Since there is an indication of abnormal oxygen metabo- 
lism in tyrosinemia, as reflected in markedly reduced concentrations of hepatic 
GSH,  it is possible that excess SA may, via the reduction of hepatic GSH,  be 
responsible, in part, for the increased incidence of hepatoma in this disorder. 
Summary 
Succinylacetone (SA)  (4,6-dioxoheptanoic  acid)  is  an  abnormal  metabolite 
produced in patients with hereditary tyrosinemia as a consequence of  an inherited 
deficiency of fumaryl acetoacetate hydrolase activity. Patients with this disease 
are associated with a number of abnormalities, including aminoaciduria, protein- 
uria,  liver failure, commonly hepatoma, and decreased GSH concentration in 
the liver. In the course of our studies of tyrosinemia, we found that the urine of 
patients with this disorder contains material(s) that absorbs light at 315 nm. We 
investigated the nature of the 315 nm material in detail. SA was found to react 
with amino acids and protein nonenzymatically, to form stable adducts at physi- 
ological temperature and pH.  All SA adducts with amino acids and/or proteins 
exhibited an absorption peak at 315 nm. Although all amino acids reacted with 
SA, the most reactive amino acid was lysine (Lys), followed, in order, by glycine, 
methionine,  phenylalanine,  serine,  alanine,  and  glutamine.  SA-adducts  were 
unstable at pH below 6,  while they were made considerably more stable after 
reduction  with  NaBH4,  suggesting  that  SA  forms an  adduct  via  Schiff base MANABE  ET  AL.  1073 
formation. High-performance liquid chromatography (HPLC) analysis of urines 
from patients with tyrosinemia revealed the existence of SA-glycine, SA-methi- 
onine,  SA-tyrosine, and SA-phenylalanine. After digestion of urines with pro- 
teinase K, three more HPLC peaks appeared, which, all corresponded to SA-Lys 
adducts.  TLC analysis of SA-Lys showed that  SA-Lys could form as many as 
seven different adducts. No SA-adduct peaks were observed in HPLC in urines 
from normal subjects,  patients with other  forms of aminoaciduria, or patients 
with the nephrotic syndrome. In addition to amino acids and proteins, SA reacted 
with reduced  glutathione  (GSH)  and  formed a  stable  adduct.  These  findings 
suggest  that  SA  adduct  formation  with  amino  acids,  GSH,  and  proteins  is  a 
significant process occurring in tyrosinemia, and may account for certain of the 
pathologic findings in this hereditary disorder. 
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